Rossari Biotech Limited — PPTs, 16-10-2025: Investor Presentation

Rossari Biotech delivered a strong Q2 FY26! 💪

**Business Performance:** Revenue jumped 18% YoY to Rs 586.1 Cr. EBITDA grew 9% YoY to Rs 71.9 Cr, with Profit After Tax (PAT) up 5% YoY to Rs 36.9 Cr. This robust performance was driven by volume expansion across key segments: HPPC (+16%), TSC (+21%), and AHN (+29%). Core business remains solid, boasting ~15% EBITDA margin even with investments, and Institutional/B2C losses are shrinking.

**Growth Drivers or Strategy:** The company is focused on augmenting its product portfolio with sustainable solutions, driving innovation, and exploring new business lines like pet food and technical textiles. Expanding global reach and strategic acquisitions are key priorities.

**Recent Developments:** Dahej plant capacity increased by an additional 20,000 MTPA (total 1,52,500 MTPA). Unitop also added 15,000 MTPA ethoxylation capacity. The Board approved an investment of up to USD 8 million in its Saudi Arabian subsidiary to boost international presence.

**Key Financial Metrics:** Q2 FY26 Revenue: Rs 586.1 Cr. EBITDA: Rs 71.9 Cr. PAT: Rs 36.9 Cr. Exports are shining, making up 28% of overall sales, growing 36% YoY. Diluted EPS for the quarter was Rs 6.7.

**Management Commentary/Outlook:** Management highlights broad-based volume growth and expanded global operations. They expect profitability to improve as new investments pay off, fueled by innovation and global footprint expansion. Rossari looks well-positioned for future growth!